Abstract 352P
Background
Breast cancer (BC) and its treatment could disturb the reproductive system. We identified reproductive system disorders following chemotherapy in patients with BC and the determinant factors.
Methods
One hundred and twelve married female patients with BC who underwent first chemotherapy between 2018 and 2020 in Dr. Sardjito Hospital, Yogyakarta were recruited. Socio-demographic and clinical data were collected at baseline. After each chemotherapy session, the patients were interviewed about symptoms of reproductive system disorder (irregular menstruation, vaginal dryness, decreased libido, dyspareunia, delayed orgasm and anorgasmia) and other symptoms (fatigue, anorexia, nausea and anxiety). We used a questionnaire based on the CTCAE version 4. Data of symptoms were collected until patients received at least 3 treatment cycles. Chi square and Fisher’s exact tests were used to analyze any association among variables.
Results
The most common symptoms were vaginal dryness (41.1%) followed by decreased libido (39.3%). In the subgroup analysis, the most common symptom among 44 pre-menopause women was irregular menstruation (84.1%). Vaginal dryness occurred more in cases with anthracycline-based regimen (p=0.036) and with anxiety (p=0.019), compared to their counterparts. Decreased libido presented more in cases with younger age (p=0.037) and positive ER status (p=0.009). Irregular menstruation, dyspareunia, delayed orgasm, and anorgasmia did not correlate with any of the determinant factors.
Conclusions
Reproductive system disorders occurred very frequently in the local BC patients after receiving chemotherapy. Influencing factors included anthracycline-based regimen, anxiety, age, and estrogen receptor status.
Clinical trial identification
Editorial acknowledgement
Erik Christopher Hookom, BA, M.Ed, TEFL Office of Research and Publication, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada.
Legal entity responsible for the study
The authors.
Funding
The Indonesian Ministry of Research, Technology, and Higher Education; Public Funding, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
210P - Prognostic value of sarcopenia in metastatic renal cell carcinoma patients: A systematic review
Presenter: Angeline Tancherla
Session: e-Poster Display Session
211P - The impact of low muscle mass to overall survival in bladder cancer patients undergoing chemotherapy: A systematic review and meta-analysis
Presenter: Karunia Japar
Session: e-Poster Display Session
212P - Stage I non-seminoma testicular cancer: Adjuvant management and outcomes
Presenter: Gaik Tin Quah
Session: e-Poster Display Session
213P - Stage I seminoma testicular cancer: Predictors of relapse and outcomes for adjuvant carboplatin vs active surveillance
Presenter: Gaik Tin Quah
Session: e-Poster Display Session
214P - Study of treatment outcome in adults with TFE related RCC
Presenter: Ajaykumar Singh
Session: e-Poster Display Session
215P - Analysis of spatial heterogeneity of responses in metastatic sites with nivolumab in renal cell carcinoma
Presenter: Venkata Pradeep Babu Koyyala
Session: e-Poster Display Session
216P - Clinical profile and treatment outcome of testicular seminoma treated at tertiary care centre in Chennai
Presenter: Sivasubramaniam Kumaravelu
Session: e-Poster Display Session
220P - A cost-effectiveness analysis of systemic therapy for metastatic hormone-sensitive prostate cancer
Presenter: Winnie Sung
Session: e-Poster Display Session
221P - Patient-reported sexual and urinary function in nonmetastatic castration-resistant prostate cancer (nmCRPC) when treated with apalutamide (APA) vs placebo (PBO) and ongoing androgen deprivation therapy (ADT) in SPARTAN
Presenter: Hiroji Uemura
Session: e-Poster Display Session
222P - Tolerability and treatment response to darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) in the phase III ARAMIS trial
Presenter: Matthew R. Smith
Session: e-Poster Display Session